The FDA's Office of Prescription Drug Promotion said in a note to Citius and Akrimax that their website for weight-loss drug Suprenza omits material information, such as risk factors for certain patients and the patient population for which the drug is indicated. The OPDP also said the use of the word "lean" in the ad misleads consumers into thinking they will become slim or slender if they take the drug, but leanness was not a primary endpoint in clinical trials.

Related Summaries